Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,607.81 in Stock

Key Points

• Major shareholder Bioventures 2018 L.P. Mpm sold 28,837 Entrada Therapeutics shares at an average price of $7.13, generating $205,607.81. The sale reduced its stake by 0.74% to 3.89 million shares, and followed several other sales in recent weeks.
• Entrada Therapeutics shares fell 5.5% to $7.11, with the stock trading well below its 52-week high of $16.45. The company’s latest quarterly results missed expectations, reporting a $1.01 loss per share and $0.90 million in revenue.
• Analyst sentiment remains mixed but leans positive: four analysts rate the stock a Buy, one rates it Hold and one Sell, producing a consensus “Moderate Buy” rating and an average price target of $17.75.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the sale, the insider directly owned 3,885,115 shares of the company's stock, valued at approximately $27,700,869.95. This trade represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.41, for a total value of $1,426,425.00.
• On Friday, September 4th, Bioventures 2018 L.P. Mpm sold 38,500 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.11, for a total value of $273,735.00.
• On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.17, for a total value of $231,325.71.
• On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total value of $180,691.89.
• On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $205,361.28.
• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.99, for a total value of $309,370.41.
• On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Trading Down 5.5%

NASDAQ TRDA traded down $0.41 during trading hours on Wednesday, hitting $7.11. 381,776 shares of the company's stock traded hands, compared to its average volume of 247,577. The business's fifty day moving average price is $7.05 and its two-hundred day moving average price is $9.09. The firm has a market capitalization of $276.86 million, a P/E ratio of -1.80 and a beta of -0.25. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, sell-side analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TRDA shares. Wall Street Zen upgraded Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings raised Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 31st. Roth Capital reiterated a "buy" rating and set a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Finally, Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating on the stock in a research note on Monday, June 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.75.

Institutional Trading of Entrada Therapeutics

Large investors have recently made changes to their positions in the business. 5AM Venture Management LLC bought a new position in shares of Entrada Therapeutics in the 2nd quarter valued at about $29,854,949. BlackRock Inc. bought a new stake in Entrada Therapeutics during the second quarter worth approximately $19,013,000. Millennium Management LLC raised its position in Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company's stock valued at $4,852,000 after purchasing an additional 666,287 shares during the period. Nantahala Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $2,212,232. Finally, Citadel Advisors LLC boosted its holdings in shares of Entrada Therapeutics by 234.5% in the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company's stock worth $1,947,000 after purchasing an additional 235,384 shares during the period. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.